



Tofacitinib Citrate Extended-Release Tablets Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-27	115	PDF
Single User	Multi User	Enterprise	
USD 2,950	USD 4,430	USD 5,900	

Description

The global Tofacitinib Citrate Extended-Release Tablets market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Tofacitinib Citrate Extended-Release Tablets is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Tofacitinib Citrate Extended-Release Tablets is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Tofacitinib Citrate Extended-Release Tablets include Yichang Humanwell Pharmaceutical, Sichuan Kelun Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lepu Pharmaceutical, Sino Therapeutics, Zydus and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Tofacitinib Citrate Extended-Release Tablets market in terms of revenue (US\$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tofacitinib Citrate Extended-Release Tablets Market by Company

Yichang Humanwell Pharmaceutical

Sichuan Kelun Pharmaceutical

CSPC Ouyi Pharmaceutical

Qilu Pharmaceutical

Lepu Pharmaceutical

Sino Therapeutics

Zydus

Pfizer

Tofacitinib Citrate Extended-Release Tablets Segment by Type

11mg per Tablet

22mg per Tablet

Tofacitinib Citrate Extended-Release Tablets Segment by Application

Rheumatoid Arthritis

Psoriatic Arthritis

Ankylosing Spondylitis

Ulcerative Colitis

Other

Tofacitinib Citrate Extended-Release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tofacitinib Citrate Extended-Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tofacitinib Citrate Extended-Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tofacitinib Citrate Extended-Release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Tofacitinib Citrate Extended-Release Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Tofacitinib Citrate Extended-Release Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Tofacitinib Citrate Extended-Release Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Tofacitinib Citrate Extended-Release Tablets Market Size (2021-2032)
 - 2.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales (2021-2032)
 - 2.2.3 Global Tofacitinib Citrate Extended-Release Tablets Market Average Price (2021-2032)
- 2.3 Tofacitinib Citrate Extended-Release Tablets by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 11mg per Tablet
 - 2.3.3 22mg per Tablet
- 2.4 Tofacitinib Citrate Extended-Release Tablets by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Rheumatoid Arthritis
 - 2.4.3 Psoriatic Arthritis
 - 2.4.4 Ankylosing Spondylitis
 - 2.4.5 Ulcerative Colitis
 - 2.4.6 Other

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Tofacitinib Citrate Extended-Release Tablets Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tofacitinib Citrate Extended-Release Tablets Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue of Manufacturers (2021-2026)
- 3.4 Global Tofacitinib Citrate Extended-Release Tablets Average Price by Manufacturers (2021-2026)
- 3.5 Global Tofacitinib Citrate Extended-Release Tablets Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Product Type & Application
- 3.8 Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Established Date
- 3.9 Global Tofacitinib Citrate Extended-Release Tablets Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Yichang Humanwell Pharmaceutical
 - 4.1.1 Yichang Humanwell Pharmaceutical Company Information
 - 4.1.2 Yichang Humanwell Pharmaceutical Business Overview
 - 4.1.3 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio

- 4.1.5 Yichang Humanwell Pharmaceutical Recent Developments
- 4.2 Sichuan Kelun Pharmaceutical
 - 4.2.1 Sichuan Kelun Pharmaceutical Company Information
 - 4.2.2 Sichuan Kelun Pharmaceutical Business Overview
 - 4.2.3 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
 - 4.2.5 Sichuan Kelun Pharmaceutical Recent Developments
- 4.3 CSPC Ouyi Pharmaceutical
 - 4.3.1 CSPC Ouyi Pharmaceutical Company Information
 - 4.3.2 CSPC Ouyi Pharmaceutical Business Overview
 - 4.3.3 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
 - 4.3.5 CSPC Ouyi Pharmaceutical Recent Developments
- 4.4 Qilu Pharmaceutical
 - 4.4.1 Qilu Pharmaceutical Company Information
 - 4.4.2 Qilu Pharmaceutical Business Overview
 - 4.4.3 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
 - 4.4.5 Qilu Pharmaceutical Recent Developments
- 4.5 Lepu Pharmaceutical
 - 4.5.1 Lepu Pharmaceutical Company Information
 - 4.5.2 Lepu Pharmaceutical Business Overview
 - 4.5.3 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
 - 4.5.5 Lepu Pharmaceutical Recent Developments
- 4.6 Sino Therapeutics
 - 4.6.1 Sino Therapeutics Company Information
 - 4.6.2 Sino Therapeutics Business Overview
 - 4.6.3 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio
 - 4.6.5 Sino Therapeutics Recent Developments
- 4.7 Zydus
 - 4.7.1 Zydus Company Information
 - 4.7.2 Zydus Business Overview
 - 4.7.3 Zydus Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio
 - 4.7.5 Zydus Recent Developments
- 4.8 Pfizer
 - 4.8.1 Pfizer Company Information
 - 4.8.2 Pfizer Business Overview
 - 4.8.3 Pfizer Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio
 - 4.8.5 Pfizer Recent Developments

5 Global Tofacitinib Citrate Extended-Release Tablets Market Scenario by Region

- 5.1 Global Tofacitinib Citrate Extended-Release Tablets Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021-2032

- 5.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021-2026
- 5.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2027-2032
- 5.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2021-2032
 - 5.3.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2021-2026
 - 5.3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2027-2032
- 5.4 North America Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
 - 5.4.1 North America Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
 - 5.4.3 North America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
- 5.5 Europe Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
 - 5.5.1 Europe Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
 - 5.5.3 Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Russia
 - 5.5.9 Spain
 - 5.5.10 Netherlands
 - 5.5.11 Switzerland
 - 5.5.12 Sweden
 - 5.5.13 Poland
- 5.6 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
 - 5.6.1 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 Taiwan
 - 5.6.10 Southeast Asia
- 5.7 South America Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
 - 5.7.1 South America Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
 - 5.7.3 South America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
 - 5.7.4 Brazil
 - 5.7.5 Argentina
 - 5.7.6 Chile
- 5.8 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
 - 5.8.1 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
 - 5.8.2 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
 - 5.8.3 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)

- 5.8.4 Egypt
 - 5.8.5 South Africa
 - 5.8.6 Israel
 - 5.8.7 Türkiye
 - 5.8.8 GCC Countries
-

6 Segment by Type

- 6.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032)
 - 6.1.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032) & (K Units)
 - 6.1.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2032)
 - 6.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032)
 - 6.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032) & (US\$ Million)
 - 6.2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2032)
 - 6.3 Global Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2032)
-

7 Segment by Application

- 7.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032)
 - 7.1.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032) & (K Units)
 - 7.1.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2032)
 - 7.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032)
 - 7.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032) & (US\$ Million)
 - 7.2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2032)
 - 7.3 Global Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2032)
-

8 Value Chain and Sales Channels Analysis of the Market

- 8.1 Tofacitinib Citrate Extended-Release Tablets Value Chain Analysis
 - 8.1.1 Tofacitinib Citrate Extended-Release Tablets Key Raw Materials
 - 8.1.2 Raw Materials Key Suppliers
 - 8.1.3 Tofacitinib Citrate Extended-Release Tablets Production Mode & Process
 - 8.2 Tofacitinib Citrate Extended-Release Tablets Sales Channels Analysis
 - 8.2.1 Direct Comparison with Distribution Share
 - 8.2.2 Tofacitinib Citrate Extended-Release Tablets Distributors
 - 8.2.3 Tofacitinib Citrate Extended-Release Tablets Customers
-

9 Global Tofacitinib Citrate Extended-Release Tablets Analyzing Market Dynamics

- 9.1 Tofacitinib Citrate Extended-Release Tablets Industry Trends
 - 9.2 Tofacitinib Citrate Extended-Release Tablets Industry Drivers
 - 9.3 Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges
 - 9.4 Tofacitinib Citrate Extended-Release Tablets Industry Restraints
-

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Tofacitinib Citrate Extended-Release Tablets Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Tofacitinib Citrate Extended-Release Tablets Sales (K Units) of Manufacturers (2021-2026)
- Table 7: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Tofacitinib Citrate Extended-Release Tablets Revenue of Manufacturers (2021-2026)
- Table 9: Global Tofacitinib Citrate Extended-Release Tablets Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Tofacitinib Citrate Extended-Release Tablets Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Tofacitinib Citrate Extended-Release Tablets Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Product Type & Application
- Table 14: Global Tofacitinib Citrate Extended-Release Tablets Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Tofacitinib Citrate Extended-Release Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Yichang Humanwell Pharmaceutical Company Information
- Table 19: Yichang Humanwell Pharmaceutical Business Overview
- Table 20: Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- Table 22: Yichang Humanwell Pharmaceutical Recent Developments
- Table 23: Sichuan Kelun Pharmaceutical Company Information
- Table 24: Sichuan Kelun Pharmaceutical Business Overview
- Table 25: Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- Table 27: Sichuan Kelun Pharmaceutical Recent Developments
- Table 28: CSPC Ouyi Pharmaceutical Company Information
- Table 29: CSPC Ouyi Pharmaceutical Business Overview
- Table 30: CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- Table 32: CSPC Ouyi Pharmaceutical Recent Developments
- Table 33: Qilu Pharmaceutical Company Information
- Table 34: Qilu Pharmaceutical Business Overview
- Table 35: Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- Table 37: Qilu Pharmaceutical Recent Developments
- Table 38: Lepu Pharmaceutical Company Information
- Table 39: Lepu Pharmaceutical Business Overview
- Table 40: Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- Table 42: Lepu Pharmaceutical Recent Developments
- Table 43: Sino Therapeutics Company Information
- Table 44: Sino Therapeutics Business Overview
- Table 45: Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 46: Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- Table 47: Sino Therapeutics Recent Developments

- Table 48: Zydus Company Information
- Table 49: Zydus Business Overview
- Table 50: Zydus Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 51: Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- Table 52: Zydus Recent Developments
- Table 53: Pfizer Company Information
- Table 54: Pfizer Business Overview
- Table 55: Pfizer Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 56: Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- Table 57: Pfizer Recent Developments
- Table 58: Global Tofacitinib Citrate Extended-Release Tablets Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 59: Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2021-2026) & (K Units)
- Table 60: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2021-2026)
- Table 61: Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2027-2032) & (K Units)
- Table 62: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2027-2032)
- Table 63: Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2021-2026) & (US\$ Million)
- Table 64: Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2021-2026)
- Table 65: Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2027-2032) & (US\$ Million)
- Table 66: Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2027-2032)
- Table 67: North America Tofacitinib Citrate Extended-Release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 68: North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units)
- Table 69: North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units)
- Table 70: North America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2026) & (US\$ Million)
- Table 71: North America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2027-2032) & (US\$ Million)
- Table 72: Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units)
- Table 74: Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units)
- Table 75: Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: Asia Pacific Tofacitinib Citrate Extended-Release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 78: Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units)
- Table 79: Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units)
- Table 80: Asia Pacific Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2026) & (US\$ Million)
- Table 81: Asia Pacific Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2027-2032) & (US\$ Million)
- Table 82: South America Tofacitinib Citrate Extended-Release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 83: South America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units)
- Table 84: South America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units)
- Table 85: South America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2026) & (US\$ Million)
- Table 86: South America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2027-2032) & (US\$ Million)
- Table 87: Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 88: Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units)
- Table 89: Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units)
- Table 90: Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2026) & (US\$ Million)
- Table 91: Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2027-2032) & (US\$ Million)
- Table 92: Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2026) & (K Units)
- Table 93: Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2027-2032) & (K Units)
- Table 94: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2026)
- Table 95: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2027-2032)
- Table 96: Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2026) & (US\$ Million)
- Table 97: Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2027-2032) & (US\$ Million)
- Table 98: Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2026)
- Table 99: Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2027-2032)
- Table 100: Global Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2026) & (US\$/Unit)
- Table 101: Global Tofacitinib Citrate Extended-Release Tablets Price by Type (2027-2032) & (US\$/Unit)
- Table 102: Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2026) & (K Units)
- Table 103: Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2027-2032) & (K Units)
- Table 104: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2026)
- Table 105: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2027-2032)

- Table 106: Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2026) & (US\$ Million)
- Table 107: Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2027-2032) & (US\$ Million)
- Table 108: Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2026)
- Table 109: Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2027-2032)
- Table 110: Global Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2026) & (US\$/Unit)
- Table 111: Global Tofacitinib Citrate Extended-Release Tablets Price by Application (2027-2032) & (US\$/Unit)
- Table 112: Key Raw Materials
- Table 113: Raw Materials Key Suppliers
- Table 114: Tofacitinib Citrate Extended-Release Tablets Distributors List
- Table 115: Tofacitinib Citrate Extended-Release Tablets Customers List
- Table 116: Tofacitinib Citrate Extended-Release Tablets Industry Trends
- Table 117: Tofacitinib Citrate Extended-Release Tablets Industry Drivers
- Table 118: Tofacitinib Citrate Extended-Release Tablets Industry Restraints
- Table 119: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Tofacitinib Citrate Extended-Release Tablets Product Image
- Figure 5: Global Tofacitinib Citrate Extended-Release Tablets Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Tofacitinib Citrate Extended-Release Tablets Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Tofacitinib Citrate Extended-Release Tablets Sales (2021-2032) & (K Units)
- Figure 8: Global Tofacitinib Citrate Extended-Release Tablets Average Price (US\$/Unit) & (2021-2032)
- Figure 9: 11mg per Tablet Product Image
- Figure 10: 22mg per Tablet Product Image
- Figure 11: Rheumatoid Arthritis Product Image
- Figure 12: Psoriatic Arthritis Product Image
- Figure 13: Ankylosing Spondylitis Product Image
- Figure 14: Ulcerative Colitis Product Image
- Figure 15: Other Product Image
- Figure 16: Global Tofacitinib Citrate Extended-Release Tablets Revenue Share by Manufacturers in 2025
- Figure 17: Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Manufacturing Sites & Headquarters
- Figure 18: Global Top 5 and 10 Tofacitinib Citrate Extended-Release Tablets Players Market Share by Revenue in 2025
- Figure 19: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 20: Global Tofacitinib Citrate Extended-Release Tablets Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 21: Global Tofacitinib Citrate Extended-Release Tablets Sales by Region in 2025
- Figure 22: Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region in 2025
- Figure 23: North America Tofacitinib Citrate Extended-Release Tablets Market Size by Country in 2025
- Figure 24: North America Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032)
- Figure 25: North America Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Country (2021-2032)
- Figure 26: United States Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Canada Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Mexico Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 29: Europe Tofacitinib Citrate Extended-Release Tablets Market Size by Country in 2025
- Figure 30: Europe Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032)
- Figure 31: Europe Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Country (2021-2032)
- Figure 32: Germany Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: France Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: U.K. Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Italy Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Russia Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Spain Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Netherlands Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Switzerland Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Sweden Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Poland Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Asia Pacific Tofacitinib Citrate Extended-Release Tablets Market Size by Country in 2025
- Figure 43: Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032)
- Figure 44: Asia Pacific Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Country (2021-2032)
- Figure 45: China Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: Japan Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: South Korea Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 48: India Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Australia Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Taiwan Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Southeast Asia Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Southeast Asia Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: South America Tofacitinib Citrate Extended-Release Tablets Market Size by Country in 2025
- Figure 54: South America Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032)
- Figure 55: South America Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Country (2021-2032)
- Figure 56: Brazil Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Argentina Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Chile Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Market Size by Country in 2025
- Figure 60: Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2032)
- Figure 61: Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Country (2021-2032)
- Figure 62: Egypt Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: South Africa Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: Israel Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Türkiye Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: GCC Countries Tofacitinib Citrate Extended-Release Tablets Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2032)
- Figure 68: Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2032)
- Figure 69: Global Tofacitinib Citrate Extended-Release Tablets Price (US\$/Unit) by Type (2021-2032)
- Figure 70: Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2032)
- Figure 71: Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2032)
- Figure 72: Global Tofacitinib Citrate Extended-Release Tablets Price (US\$/Unit) by Application (2021-2032)
- Figure 73: Tofacitinib Citrate Extended-Release Tablets Value Chain
- Figure 74: Tofacitinib Citrate Extended-Release Tablets Production Mode & Process
- Figure 75: Direct Comparison with Distribution Share
- Figure 76: Distributors Profiles
- Figure 77: Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges